Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
66 studies found for:    Open Studies | "Vitamin K"
Show Display Options
Rank Status Study
21 Recruiting Biomarkers and Antithrombotic Treatment in Cervical Artery Dissection - TREAT-CAD
Condition: Cervical Artery Dissection
Interventions: Drug: Acetylsalicylic acid;   Drug: vitamin K-antagonist
22 Recruiting Aortic Calcification and Vitamin K Antagonists
Condition: Vascular Calcification
Intervention:
23 Not yet recruiting Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
Conditions: Atrial Fibrillation;   End-stage Kidney Disease
Interventions: Drug: Apixaban;   Drug: Phenprocoumon
24 Recruiting Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Conditions: Severe Bleeding;   Urgent Surgery
Intervention:
25 Recruiting An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding
Condition: Hemorrhage
Interventions: Biological: Kcentra®;   Biological: Plasma
26 Not yet recruiting Oral Anticoagulation in Haemodialysis Patients
Condition: Kidney Failure, Chronic
Interventions: Biological: No oral anticoagulation, and no monitoring of the INR.;   Drug: Oral anticoagulation with vitamin K antagonists
27 Not yet recruiting Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 75 Years and Over Suffering From Non Valvular Atrial Fibrillation (nv AF)
Condition: Non Valvular Atrial Fibrillation (nv AF)
Interventions: Drug: Non-exposed group;   Drug: Exposed group
28 Recruiting PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma
Conditions: Coagulation; Intravascular;   Craniocerebral Trauma;   Haemorrhage
Intervention: Procedure: Reversion
29 Recruiting Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
Condition: Unsuspected Pulmonary Embolism
Intervention: Drug: Heparin, fondaparinux, vitamin-K antagonists, aspirin
30 Not yet recruiting INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority
Condition: Rheumatic Heart Disease
Interventions: Drug: Rivaroxaban (15 mg);   Drug: Aspirin
31 Recruiting Rivaroxaban Compared to Vitamin K Antagonist Upon Development of Cardiovascular Calcification
Conditions: Atrial Fibrillation or Pulmonary Embolism;   Need of Long Term Oral Anticoagulation Therapy (OAT);   Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location
Intervention: Drug: Rivaroxaban or Marcumar
32 Recruiting A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart
Condition: Acute Coronary Syndromes
Interventions: Drug: Apixaban;   Drug: vitamin K antagonist;   Drug: Acetylsalicylic acid;   Other: Acetylsalicylic acid placebo
33 Not yet recruiting Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
Condition: Significant Bleeding Risk
Interventions: Drug: Octaplex;   Drug: Beriplex P/N (Kcentra)
34 Not yet recruiting Tecarfarin Anti-Coagulation Trial (TACT)
Conditions: Thromboembolism;   Thrombosis
Interventions: Drug: Warfarin;   Drug: tecarfarin
35 Recruiting Novel Oral Anticoagulants in Stroke Patients
Conditions: Ischemic Stroke;   Intracranial Hemorrhages
Intervention:
36 Recruiting RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism
Condition: Venous Thromboembolism
Intervention:
37 Recruiting Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation
Conditions: Permanent Atrial Fibrillation;   Venous Thrombosis;   Pulmonary Embolism;   Anticoagulation Treatment at Least > or = to 12-month
Interventions: Drug: Rivaroxaban;   Drug: Fluindione;   Drug: Warfarin
38 Recruiting Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Condition: Atrial Fibrillation
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Vitamin K antagonists;   Drug: dabigatran (Pradaxa)
39 Recruiting Pharmacokinetic Drug-Drug Interaction Study of Rucaparib
Condition: Neoplasms
Interventions: Drug: Caffeine;   Drug: Warfarin;   Drug: Omeprazole;   Drug: Midazolam;   Drug: digoxin;   Drug: Vitamin K;   Drug: Rucaparib
40 Not yet recruiting Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
Condition: Atrial Fibrillation
Interventions: Drug: Edoxaban;   Drug: VKA-Based Regimen

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.